Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence

Health Policy

Volumn 100, Issue 2-3, 2011, Pages 134-143

  Faden, Laura ^a   Vialle Valentin, Catherine ^a   Ross Degnan, Dennis ^a   Wagner, Anita ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; Drug utilization; Essential medicines; Health insurance; Health policy

Indexed keywords

COST BENEFIT ANALYSIS; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; LOWEST INCOME GROUP; MANAGEMENT STYLE; MEDICAL EDUCATION; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRESCRIPTION; PUBLICATION; REVIEW;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HUMANS; INSURANCE, HEALTH; INSURANCE, PHARMACEUTICAL SERVICES;

EID: 79954860749     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.10.020     Document Type: Review

References (94)

1. Laing R., Waning B., Gray A., Ford N., 't Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet 2003, 361(9370):1723-1729.
2. World Health Organization Equitable access to essential medicines: a framework for collective action 2004, World Health Organization, Geneva.
3. United Nations. The millennium development goals report (MDG Goal #8, target #4). New York; 2008.
4. Second International Conference of Improving Use of Medicines (ICIUM). ICIUM 2004 Conference Recommendations: Insurance Coverage. Accessed at: ; 2004. http://archives.who.int/icium/icium2004/recommendations.html.
5. Quick J. Ensuring access to essential medicines in developing countries-A framework for action. Clinical Pharmacology and Therapeutics 2003, 73(4):279-283.
6. Yip W., Hsiao W.C. Non-evidence-based policy. How effective is China's New Cooperative Medical Scheme in reducing medical impoverishment. Social Science & Medicine 2009, 68:201-209.
7. Wagner A.K., Graves A.J., Reiss S.K., Lecates R., Zhang F., Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. Health Policy 2011, 100:151-158.
8. Gibson T.B., Ozminkowski R.J., Goetzel R.Z. The effects of prescription drug cost sharing: a review of the evidence. The American Journal of Managed Care 2005, 11:730-740.
9. Goldman D.P., Joyce G.F., Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. The Journal of the American Medical Association 2007, 298:61-69.
10. Dror D.M., Koren R., Ost A., Binnendijk E., Vellakkal S., Danis M. Health insurance benefit packages prioritized by low-income clients in India: three criteria to estimate effectiveness of choice. Social Science & Medicine 2007, 64(4):884-896.
11. Wagner A.K., Ross-Degnan D. Insurance systems in the Asia-Pacific region: Improving appropriate use of and access to medicines. Prescribing cultures and pharmaceutical policy in the Asia Pacific 2009, 313-335. The Walter H. Shorenstein Asia-Pacific Research Center Books, Stanford. K. Eggleston (Ed.).
12. Carrin G., Mathauer I., Xu K., Evans D.B. Universal coverage of health services: tailoring its implementation. Bulletin of the World Health Organization 2008, 86(November (11)):857-863.
13. The World Bank. Data and statistics: country classification. Available at: ; 2009. http://web.worldbank.org/.
14. OECD Health Policy Studies Pharmaceutical pricing policies in a global market 2008, OECD.
15. Hoadley J. Cost containment strategies for prescription drugs: assessing the evidence of the literature. Report prepared for the Kaiser Family Foundation; 2005.
16. Soumerai S.B., Ross-Degnan D., Fortess E.E., Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Quarterly 1993, 71(2):217-252.
17. Lu C.Y., Ross-Degnan D., Soumerai S.B., Pearson S. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature-2001-2007. BMC Health Services Research 2008, 8:75.
18. Armour B.S., Pitts M.M., Maclean R., Cangialose C., Kishel M., Imai H., et al. The effect of explicit financial incentives on physician behavior. Archives of Internal Medicine 2001, 161(10):1261-1266.
19. Sturm H., Austvoll-Dahlgren A., Aaserud M., Oxman A.D., Ramsay C., Vernby A., et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database of Systematic Reviews 2007, 3.
20. Ostini R., Hegney D., Jackson C., Williamson M., Mackson J.M., Gurman K., et al. Systematic review of interventions to improve prescribing. The Annals of Pharmacotherapy 2009, 43(3):502-513.
21. Tetteh E.K. Policies and institutional arrangements for rationalizing drug selection and consumption patterns in African healthcare systems. Research in Social & Administrative Pharmacy 2009, 5(3):274-285.
22. Seiter A. A practical approach to pharmaceutical policy 2010, The World Bank, pp. 110-113.
23. Gakidou E., Lozano R., González-Pier E., Abbott-Klafter J., Barofsky J.T., Bryson-Cahn C., et al. Assessing the effect of the 2001-06 Mexican health reform: an interim report card. Lancet 2006, 368(9550):1920-1935.
24. Hotchkiss D.R., Hutchinson P.L., Malaj A., Berruti A.A. Out-of-pocket payments and utilization of health care services in Albania: evidence from three districts. Health Policy 2005, 75(December (1)):18-39.
25. Lima-Costa M.F.F., Guerra H.L., Firmo J.O.A., Vidigal P.G., Uchoa E., Barreto S.M. The Bambuí Health and Aging Study (BHAS): private health plan and medical care utilization by older adults. Cadernos de Saude Publica 2002, 18(1):177-186.
26. King G., Gakidou E., Imai K., Lakin J., Moore R.T., Nall C., et al. Public policy for the poor? A randomised assessment of the Mexican universal health insurance programme. Lancet 2009, 373(9673):1447-1454.
27. Frenk J., Gómez-Dantés O., Knaul F.M. The democratization of health in Mexico: financial innovations for universal coverage. Bulletin of the World Health Organization 2009, 87(7):542-548.
28. Arrais P.S.D., Brito L.L., Barreto M.L., Coelho H.L.L. Prevalence and determinants of medicines consumption in Fortaleza, Ceará, Brazil. Cadernos de Saude Publica 2005, 21(6):1737-1746.
29. Maurer J. Assessing horizontal equity in medication treatment among elderly Mexicans: which socioeconomic determinants matter most?. Health Economics 2008, 17(10):1153-1169.
30. Chotigeat U., Promwong N., Kanjanapattanakul W., Khorana M., Sangtawesin V., Horpaopan S. Comparison outcomes of surfactant therapy in respiratory distress syndrome in two periods. Journal of the Medical Association of Thailand 2008, 91(Suppl. 3):S109-S114.
31. Palesh M., Jonsson P.M., Jamshidi H., Wettermark B., Tomson G., Fredrikson S. Diffusion of interferon beta in Iran and its utilization in Tehran. Pharmacoepidemiology and Drug Safety 2008, 17(9):934-941.
32. Steyn K., Bradshaw D., Norman R., Bradley H., Laubscher R. The use of prescribed drugs for common chronic conditions in South Africa in 1998. Pharmacoepidemiology and Drug Safety 2005, 14(2):91-100.
33. Garrido-Latorre F., Hernández-Llamas H., Gómez-Dantés O. Dispensing prescriptions to persons affiliated with the Seguro Popular de Salud de México. Salud publica de Mexico 2008, 50(Suppl. 4):S429-S436.
34. Dror D.M., Soriano E.S., Lorenzo M.E., Sarol J.N., Azcuna R.S., Koren R. Field based evidence of enhanced healthcare utilization among persons insured by micro health insurance units in Philippines. Health Policy 2005, 73(3):263-271.
35. Sosa-Rubí S.G., Galárraga O., López-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bulletin of the World Health Organization 2009, 87(7):512-519.
36. Bleich S.N., Cutler D.M., Adams A.S., Lozano R., Murray C.J.L. Impact of insurance and supply of health professionals on coverage of treatment for hypertension in Mexico: population based study. BMJ 2007, 335(7625):875.
37. Moreira E.D., De Siqueira I.C., Alcantara A.P., Guereiro De Moura C.G., De Carvalho W.A., Riley L. Antimicrobial resistance of Escherichia coli strains causing community-acquired urinary tract infections among insured and uninsured populations in a large urban center. Journal of Chemotherapy 2006, 18(3):255-260.
38. Chang F., Trivedi P.K. Economics of self-medication: theory and evidence. Health Economics 2003, 12(9):721-739.
39. Pagán J.A., Ross S., Yau J., Polsky D. Self-medication and health insurance coverage in Mexico. Health Policy 2006, 75(2):170-177.
40. Saradamma R.D., Higginbotham N., Nichter M. Social factors influencing the acquisition of antibiotics without prescription in Kerala State, south India. Social Science & Medicine 2000, 50(6):891-903.
41. Hadi U., Duerink D.O., Lestari E.S., Nagelkerke N.J., Werter S., Keuter M., et al. Survey of antibiotic use of individuals visiting public healthcare facilities in Indonesia. International Journal of Infectious Diseases 2008, 12(6):622-629.
42. Dong H. Health financing policies: patient care-seeking behavior in rural China. International Journal of Technology Assessment in Health Care 2003, 19(3):526-532.
43. Hu S., Chen W., Cheng X., Chen K., Zhou H., Wang L. Pharmaceutical cost-containment policy: experiences in Shanghai, China. Health Policy and Planning 2001, 16(Suppl. 2):4-9.
44. Lang H., Lai M., Chen G. Outpatient drug expenditures and prescription policies for diseases with high cost to the National Health Insurance system in Taiwan. Journal of the Formosan Medical Association 2004, 103(4):280-285.
45. Zhu M., Dib H.H., Zhang X., Tang S., Liu L. The influence of health insurance towards accessing essential medicines: the experience from Shenzhen labor health insurance. Health Policy 2008, 88(2-3):371-380.
46. Kim H.J., Chung W., Lee S.G. Lessons from Korea's pharmaceutical policy reform: the separation of medical institutions and pharmacies for outpatient care. Health Policy 2004, 68(3):267-275.
47. Yang B., Bae E., Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Affairs 2008, 27(1):179-187.
48. Liu S., Romeis J.C. Changes in drug utilization following the outpatient prescription drug cost-sharing program-evidence from Taiwan's elderly. Health Policy 2004, 68(3):277-287.
49. Lee Y., Yang M., Huang Y., Liu C., Chen S. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006, 24(9):891-902.
50. Chankova S., Sulzbach S., Diop F. Impact of mutual health organizations: evidence from West Africa. Health Policy Planning 2008, 23(4):264-276.
51. Kutzin J. Health financing policy paper: program successes in Kyrgyzstan: new co-payments increase health financing technology 2008, The Regional Office for Europe of the World Health Organization, Division of Country Health Systems. http://www.euro.who.int/document/e91422.pdf.
52. Homedes N., Ugalde A. Multisource drug policies in Latin America: survey of 10 countries. Bulletin of the World Health Organization 2005, 83(1):64-70.
53. Gossell-Williams M. Generic substitution: a 2005 survey of the acceptance and perceptions of physicians in Jamaica. West Indian Medical Journal 2007, 56(5):458-463.
54. National Association of Pharmaceutical Manufacturers The generic pharmaceutical market in South Africa: at the crossroads?. Journal of Generic Medicine 2009, 6(2):137-144.
55. Ratanawijitrasin S. Pharmaceutical policy in Thailand: a review of three decades of government interventions. Prescribing cultures and pharmaceutical policy in the Asia Pacific 2009, 79-106. The Walter H. Shorenstein Asia-Pacific Research Center Books, Stanford. K. Eggleston (Ed.).
56. Hirunrassamee S., Ratanawijitrasin S. Does your health care depend on how your insurer pays providers? Variation in utilization and outcomes in Thailand. International Journal of Health Care Finance and Economics 2009, 9(2):153-168.
57. Pitaknetinan K., Tangcharoensathien V., Supachutikul A., Bennett S., Mills A. Profit, payment and pharmaceutical practices: perspectives from hospitals in Bangkok. Health Policy 1999, 46(3):179-194.
58. Mills A., Bennett S., Siriwanarangsun P., Tangcharoensathien V. The response of providers to capitation payment: a case-study from Thailand. Health Policy 2000, 51(3):163-180.
59. Moïse P, Docteur E. Pharmaceutical pricing and reimbursement in Mexico. OECD Health Working Papers; 2007.
60. Kutzin J, Ibrahimova A, Kadyrova N, Isabekova G, Samyshkin Y, Kataganova Z. Resource allocation and purchasing in the Kyrgyz health care system. Report to the World Bank and Ministry of Health; 2000.
61. Ibraimova, A, Cashin C, Waning B. Use of automated claims data in the Kyrgyzstan outpatient drug benefit program to evaluate medicine pricing trends plus access and equity among beneficiaries. Presentation at ICIUM 2004, ; 2004. http://www.icium.org/icium2004/resources/ppt/O_AC121.ppt.
62. Rothberg A.D., Blignault J., Serfontein C.B., Valodia B., Eekhout S., Pels L.M. Experience of a medicines reference-pricing model. South African Medical Journal 2004, 94(3):183-188.
63. Chen C., Chen L., Yang W. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs. BMC Public Health 2008, 8:118.
64. Sun X., Jackson S., Carmichael G.A., Sleigh A.C. Prescribing behaviour of village doctors under China's New Cooperative Medical Scheme. Social Science & Medicine 2009, 68(10):1775-1779.
65. Dong H., Bogg L., Rehnberg C., Diwan V. Health financing policies. Providers' opinions and prescribing behavior in rural China. International Journal of Technology Assessment in Health Care 1999, 15(4):686-698.
66. Zhou B., Yang L., Sun Q., Gu H., Wang B. Social health insurance and drug spending among cancer inpatients in China. Health Affairs 2008, 27(4):1020-1027.
67. Dong H., Bogg L., Wang K., Rehnberg C., Diwan V. A description of outpatient drug use in rural China: evidence of differences due to insurance coverage. The International Journal of Health Planning and Management 1999, 14(1):41-56.
68. Tu F., Tokunaga S., Deng Z., Nobutomo K. Analysis of hospital charges for cerebral infarction stroke inpatients in Beijing, People's Republic of China. Health Policy 2002, 59(3):243-256.
69. Price M.R. A comparison of prescribing patterns and consequent costs at Alexandra Health Centre and in the private fee-for-service medical aid sector. South African Medical Journal 1990, 78(3):158-160.
70. Dong H., Bogg L., Rehnberg C., Diwan V. Association between health insurance and antibiotics prescribing in four counties in rural China. Health Policy 1999, 48(1):29-45.
71. Yip W., Eggleston K. Addressing government and market failures with payment incentives: hospital reimbursement reform in Hainan, China. Social Science & Medicine 2004, 58(2):267-277.
72. Suttajit S., Wagner A.K., Tantipidoke R., Ross-Degnan D., Sitthi-amorn C. Patterns appropriateness, and predictors of antimicrobial prescribing for adults with upper respiratory infections in urban slum communities of Bangkok. The Southeast Asian Journal of Tropical Medicine and Public Health 2005, 36(2):489-497.
73. Laosee O.C., Pathanapornpandh N., Sitthi-amorn C., Khiewyoo J., Somrongthong R., Dulyavoranun N. Prescription pattern for treatment of hemorrhoids under the universal coverage policy of Thailand. The Southeast Asian Journal of Tropical Medicine and Public Health 2005, 36(4):1020-1024.
74. Huang C.C., Chung K., Kuo N., Hung C. Effectiveness of coping strategies used by hospitals in response to implementation of a case-based payment system by the National Health Insurance program. Journal of the Formosan Medical Association 2005, 104(7):468-475.
75. Witter S., Garshong B. Something old or something new? Social health insurance in Ghana. BMC International Health and Human Rights 2009, 9:20.
76. Chu H., Liu S., Romeis J.C. Changes in prescribing behaviors after implementing drug reimbursement rate reduction policy in Taiwan: implications for the medicare system. Journal of Health Care Finance 2008, 34(3):45-54.
77. Day K., Booyens S. The cost-effectiveness of managed care regarding chronic medicine prescriptions in a selected medical scheme. Curationis 1998, 21(December (4)):65-70.
78. Hukins G., Boyce D. Containing medicines costs in the private sector--the example of a medical benefit scheme. South African Medical Journal 1990, 78(3):152-154.
79. Quimbo S., Peabody J., Shimkhada R., Woo K., Solon O. Should we have confidence if a physician is accredited? A study of the relative impacts of accreditation and insurance payments on quality of care in the Philippines. Social Science & Medicine 2008, 67(4):505-510.
80. Lee T.-T., Cheng S.-H., Chen C.-C., Lai M.-S. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. The American Journal of Managed Care 2010, 16(1):65-69.
81. Chou Y.J., Yip W.C., Lee C., Huang N., Sun Y., Chang H. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience. Health Policy and Planning 2003, 18(3):316-329.
82. Lee Y., Huang K., Huang Y. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan. Health Policy and Planning 2007, 22(6):427-435.
83. Kim H., Ruger J.P. Pharmaceutical reform in South Korea and the lessons it provides. Health Affairs 2008, 27(4):w260-269.
84. Park S., Soumerai S.B., Adams A.S., Finkelstein J.A., Jang S., Ross-Degnan D. Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. Health Policy and Planning 2005, 20(5):302-309.
85. Family medicine at the dawn of the 21st century 2005, IMSS, Mexico City. C. Garcia-Pena, O. Munoz, L. Duran, F. Vazquez (Eds.).
86. Pérez-Cuevas R., Reyes H., Guiscafré H., Juárez-Díaz N., Oviedo M., Flores S., et al. The primary care clinic as a setting for continuing medical education: program description. Canadian Medical Association Journal 2000, 163(10):1295-1299.
87. Reyes-Morales H., Flores-Hernández S., Tomé-Sandoval P., Pérez-Cuevas R. A multifaceted education intervention for improving family physicians' case management. Family Medicine 2009, 41(4):277-284.
88. Pérez-Cuevas R., Guiscafré H., Muñoz O., Reyes H., Tomé P., Libreros V., et al. Improving physician prescribing patterns to treat rhinopharyngitis. Intervention strategies in two health systems of Mexico. Social Science & Medicine 1996, 42(8):1185-1194.
89. Guiscafre H., Martínez H., Reyes H., Pérez-Cuevas R., Castro R., Muñoz O., et al. From research to public health interventions I. Impact of an educational strategy for physicians to improve treatment practices of common diseases. Archives of Medical Research 1995, 26 Spec no::S31-S39.
90. Connelly P., Rosen S. Treatment of HIV/AIDS at South Africa's largest employers: myth and reality. South African Medical Journal 2006, 96(2):128-133.
91. Wagstaff A. Estimating health insurance impacts under unobserved heterogeneity: the case of Vietnam's health care fund for the poor. Health Economics 2010, 19(2):189-208.
92. Vialle-Valentin C.E., Ross-Degnan D., Ntaganira J., Wagner A.K. Medicines coverage and community-based health insurance in low-income countries. Health Research Policy and Systems 2008, 6:11.
93. Ratanawijitrasin S., Soumerai S.B., Weerasuriya K. Do national medicinal drug policies and essential drug programs improve drug use? A review of experiences in developing countries. Social Science & Medicine 2001, 53(7):831.
94. Pauly MV, Blavin FE, Meghan S. Is there a market for voluntary health insurance in developing countries? NBER Working Paper; 2008.